NCT07142954 · Phase 3 · RECRUITING
Epidemiology and Biomarker Study in Alzheimer's Disease
This study uses a blood test for a protein called P-tau217 to sort people with no memory problems into two groups: elevated or not elevated. Researchers then follow everyone for about 7 years to see how quickly thinking skills change in each group. No drug is given. It is listed as Phase 3, but it is an observation study.
You may qualify if
- The participant must self-report unimpaired cognition.
- The participant must have adequate literacy, vision, and hearing for neuropsychological assessments at the time of screening.
You're excluded if
- Have seen a doctor about memory concerns.
- Have a history or diagnosis of cognitive impairment, or significant other neurodegenerative disease that can affect cognition.
- Are currently enrolled or have previously participated in any Alzheimer's Disease (AD)-related study involving an investigational drug intervention.
- Are currently using or have previously used prescription medications for treatment of mild cognitive impairment (MCI) or dementia such as amyloid targeting therapy (that is, lecanemab, donanemab, aducanumab), cholinesterase inhibitors (for example, benzgalantamine, donepezil, galantamine, rivastigmine), and memantine.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-07-07